Slide background

Slide background
Slide background
Slide background

Center for Genomics of Neurodegenerative Disease Phatnani Lab

The Center for Genomics of Neurodegenerative Disease (CGND) is dedicated to the study of neurodegenerative diseases such as ALS and Alzheimer’s disease. CGND’s vision is to establish a center for applying state of the art genetics, genomics and bioinformatics to the study of neurodegenerative disease mechanisms.

CGND’s goals are to use whole genome sequencing to identify mutations that cause neurodegenerative disease. To gain insights into the relationship between mutations, gene expression and disease mechanisms, whole genome sequencing data will ultimately be integrated with other genomic-scale data such as RNA-SEQ, RNA-protein interactions, and DNA methylation patterns.

CGND is helping to create a uniform system of collecting clinical annotation to better enable the integration of genomic data with clinical profiles. This information will be freely available to the research community in a data warehouse for whole genome sequencing and RNA-SEQ analyses.



  • +
    Hemali Phatnani, PhD


    Hemali Phatnani, PhD, serves as the Director, Center for Genomics of Neurodegenerative Disease (CGND) at NYGC. She has a joint appointment as Adjunct Assistant Professor of Neurogenetics in the Department of Neurology and the Institute for Genomic Medicine at Columbia University. Her research focuses on gene regulatory mechanisms that underlie the complex interactions between motor neurons and non-neuronal cells in the spinal cord of ALS mouse models, including astrocytes, microglia and oligodendrocytes. The goal of Dr. Phatnani’s research is to apply state-of-the-art genomics and bioinformatics to understand the role of cell-cell interactions in ALS pathophysiology.

    Dr. Phatnani carried out her postdoctoral studies in Dr. Tom Maniatis’ Lab at Harvard and Columbia Universities, where she studied ALS disease mechanisms using stem cell-derived motor neurons and genomic profiling methods. She established a novel cell culture system to study cell intrinsic and cell extrinsic effects of astrocytes on motor neuron gene expression, and discovered a complex interplay between the two cell types during ALS disease progression.

    Dr. Phatnani received her PhD in biochemistry and molecular biology at Duke University, where she characterized the interactions between RNA polymerase and proteins involved in the mechanistic coupling of RNA transcription and processing. She earned a B.Sc. in life sciences from Bombay (Mumbai) University.




  • +
    Genetics and Genomics of ALS

    8dd56f_f15f686f6e0b48fea725d0773b9b077cThe vision of the Center for Genomics of Neurodegenerative Disease (CGND) at NYGC is to establish a framework to apply state-of-the-art genomics and bioinformatics to the study of neurodegenerative disease mechanisms, by building partnerships with clinicians, basic scientists, geneticists, and computational biologists.

    The CGND’s research program in Amyotrophic Lateral Sclerosis (ALS) was established with the help of generous support from The Tow Foundation and The ALS Association’s (ALSA) Greater New York Chapter. The CGND’s partners include not only NYGC’s founding members such as Columbia and Rockefeller, but also ALS centers throughout the northeast, such as the University of Pennsylvania, Massachusetts General Hospital and Hershey Medical Center at Penn State University, among others. Through the support of ALSA, our efforts also synergize with other ALSA-funded consortia, such as Answer ALS, and the GTAC (“Genomics Translation for ALS Clinical care”) consortium. In addition, we work in close partnership with Target ALS’s Post Mortem Core, iPS core, and Biospecimen Collection.

    Through a multidisciplinary collaborative effort that spans multiple ALS centers and bridges ALS clinicians and scientists, we are using whole genome sequencing to discover and study mutations and mechanisms underlying ALS. Broadly stated, the goals of this consortium are the following:

    Integrate whole genome sequencing with RNA sequencing to interrogate relationships between mutations, gene expression and disease mechanisms

    RNA sequencing analyses combined with whole genome sequencing will help us to identify how changes in DNA are expressed in the brain and spinal cord, and how this affects the presentation and course of disease.

    Integrate genomic and clinical data to identify genetic modifiers of disease onset/progression/presentation

    Our partners’ clinical phenotyping efforts will enable us to sequence well-stratified patient cohorts, so that we can eventually identify mutations that are associated with different forms of the disease, or gene variants that can modify the presentation of the disease and could be further studied to identify pathways for the targeted development of therapies.

    Create and maintain a data warehouse for genomic data that can be broadly accessed by the academic community

    Our sequencing data will be made freely available to the research community. Resource and data sharing is an integral aspect of our efforts, because we want the data that we generate to be as useful as possible to as many researchers as possible. Broad sharing will only accelerate the pace of discovery and therapeutics, which are crucially needed in ALS.

    Such broad sharing and collaborative efforts are ultimately geared towards making the best use of sequencing data. For example, comparing clinical profiles to genomic profiles can enable us to determine whether specific mutations are associated with specific clinical outcomes – this may ultimately make truly “personalized” medicine possible.

    8dd56f_137bc4273c4d4143b9b803ef64662163Design and create ALS models to test effects of mutations in stem cell derived neurons and in mouse models using state-of-the-art genomic manipulation methods.

    To study the function of any sequence variants that we identify and to understand how they affect disease mechanisms, we collaborate with our research partners to make new models of disease such as iPS cells and mouse models. We use these models to study, for example, how mutations affect the different cell types that are known to play a role in ALS, such as astrocytes, microglia, and oligodendrocytes, all of which are known to affect motor neurons in ALS. Using these models, we examine regulatory mechanisms affecting the transcriptome, as well as mechanisms underlying intercellular interactions in disease. To further these analyses, we are developing tools to integrate the experimental and computational analysis of large-scale data that includes transcriptomes of specific cell types in the Central Nervous System, profiles of RNA-binding proteins implicated in disease, and high-resolution imaging. The combination of new deep sequencing methods, sample acquisition, data analysis pipelines, and molecular and phenotypic characterizations using new mouse models will provide mechanistic insights that were previously not possible.

    Any models that we develop through our collaborative efforts will be made freely available to the research community – this is in fact a condition of any partnerships that we undertake. In addition, the conceptual framework and infrastructure should be widely applicable to other neurodegenerative diseases.

    The CGND’s ALS Consortium at-a-glance:


    1. Academic Medical Center, Amsterdam
    2. Brigham and Women’s Hospital
    3. Cedars-Sinai Medical Center
    4. Columbia University
    5. Cold Spring Harbor Laboratory
    6. Gladstone Institute
    7. Henry Ford Health System
    8. Icahn School of Medicine at Mount Sinai
    9. The Jackson Lab
    10. Johns Hopkins University
    11. Massachusetts General Hospital
    12. Massachusetts Institute of Technology
    13. National Institutes of Health’s National Institute of Neurological Disorders and Stroke
    14. New York Genome Center
    15. Queen Mary University of London
    16. Stony Brook University
    17. Temple University
    18. The Pennsylvania State University
    19. University College London
    20. University of California at Irvine
    21. University of California at San Francisco
    22. University of Edinburgh
    23. University of Maryland, Baltimore
    24. University of Pennsylvania
    25. University of Thessaly
    26. Washington University in St. Louis
    27. Weizmann Institute of Science


    Pre-competitive Data Sharing with all Consortium Members, samples consented for broad sharing for all medical research

    Partnerships: Answer ALS Consortium, GTAC Consortium, Target ALS – Post Mortem Core, Project MinE, iPS Core, Biospecimen Collection

    Target Groups: FALS, SALS, C9 carriers

    Data being collected now: DNA, autopsy tissue RNA, some iPS, clinical data (longitudinal clinical data targeted for ~1300 of a total of 1800 patients)


    1. ALS gene discovery efforts: unexplained familial ALS, increasing power through increased numbers of sporadic patients for co-analysis with existing datasets
    2. Genotype-phenotype correlations
    3. Integrating WGS with tissue-specific transcriptomics for understanding the impact of regulatory variation and cell type-specific contributions
    4. C9 promoter methylation (QTLs of this phenotype)


    Data Access:

    Consortium data is being deposited in MetroNome, NYGC’s clinical genomics database.
    To access data that is publicly available now, click here.

  • +
    Astrocytes in ALS

    8dd56f_6e0eb389fda444d4b6ebfbcbbd0bb306How neurons and glia communicate and depend on each other is still a largely open question in neuroscience. Perturbations in this interdependence underlie many neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS). Motor neuron death in ALS is a culmination of pathological processes affecting both glia, such as astrocytes, and neurons. Although astrocytes are known to contribute to motor neuron death in ALS, the mechanisms through which they do so are not well understood. Our lab has pioneered a motor neuron-astrocyte co-culture platform (‘sandwich culture’) that allows us to dissect how motor neurons and astrocytes interact over time and how these interactions are affected in disease. It is known that expressing an ALS causing human transgene (SOD1 G93A) in either cell type causes a reciprocal up-regulation of Transforming Growth Factor Beta (TGF-ß) signaling genes between the two cell types. TGF-ß signaling is implicated in many neurodegenerative diseases including sporadic and familial ALS. We are currently investigating the pathological significance of dysregulation of this pathway is SOD1 G93A and FUS ALS models.

  • +
    Detecting Repeat Expansions

    8dd56f_85454bdd654f452ebe746b8735857cb1Several recent studies have identified a specific type of genetic mutation called a repeat expansion (RE) in chromosome 9 open reading frame 72 (C9orf72) to be the most common cause of familial amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). This type of mutation is common in neurodegenerative diseases; the RE in ALS-FTLD consists of six base pairs (GGGGCC) repeated 100’s to 1000’s of times. Among C9orf72 RE patients, there is considerable heterogeneity in age of onset, disease severity, phenotypic presentation, and the total length of the RE. Several potential mechanisms of disease related to the C9orf72 RE have been proposed: aberrant RNA splicing and translocation, aggregation of dipeptides resulting from non-ATG mediated translation, nucleocytoplasmic export dysfunction, and neuronal branching defects. The length of RE necessary to cause these functional abnormalities and its relationship to disease presentation, however, remain unclear. At NYGC, James is using cutting edge molecular biology and next generation sequencing to investigate the C9orf72 RE and its contribution to ALS-FTLD.

  • +
    Cell Type Specific Translatomics


    We are also taking ‘functional genomics’ approach to ALS disease progression  in vivo by developing  biochemical protocols and bioinformatics pipelines to interrogate transcriptome, translatome and epigenome dynamics in a cell type-specific manner in mouse models of ALS. The computational integration of these datasets will decipher the inter-cellular communication and intra-cellular responses during disease advancement at high temporal resolution. These molecular insights will form a fundamental basis for the discovery of new disease biomarkers, and to identify targets for next-generation therapeutics including antisense oligonucleotides to modulate RNA levels, splicing or post-transcriptional regulation.


  • +
    Cell Type Specific Transcriptomics


    Dynamic regulation of gene expression is a key feature of virtually all aspects of cellular function. Changes in gene expression patterns can reveal the presence of disease, and understanding such changes can yield insight into the basic biology of disease. Recent rapid advances in sequencing technologies have dramatically enhanced our ability to collect gene expression data. However, using the most widely available high throughput sequencing methods, measurement of gene expression in complex tissues is hampered by the need to homogenize or dissociate the tissues. In both cases, positional information is lost. The few high throughput methods for measuring gene expression while preserving spatial information that exist are prohibitively complex, labor intensive, expensive, and require specialized equipment. Thus, a need exists for technologies with which to capture high content spatial gene expression data, that are easier, cheaper, and more widely usable than existing technologies. Studies of neurodegenerative diseases in particular can benefit immensely from a better understanding of how gene expression differs across tissues, cell types, and sub-cellular domains. Motor neurons, the key affected cell type in ALS, can be on the order of a meter long. Such large cells must precisely control not only the amount, but also the localization of RNAs and proteins along that length to function properly. Moreover, subpopulations of motor neurons residing near each other can exhibit different levels of vulnerability to the disease. Substantial evidence now indicates that ALS disease progression involves signaling between neurons and glia, but the nature of this signaling and how it is involved in the spread of the disease state along the spinal cord remain poorly understood. Thus, a better view of how cells of the spinal cord alter the expression of their genes across both spatial and temporal dimensions during disease progression will inform our understanding of ALS. We are developing and utilizing microscopy and molecular techniques in efforts to understand the changes in gene expression patterns that occur in ALS.

  • +
    • +
      Robert Darnell, MD, PhD


      Robert B. Darnell, M.D., Ph.D., is Founding Director and CEO of the New York Genome Center. He also serves as the Robert and Harriet Heilbrunn Professor and Senior Attending Physician at The Rockefeller University and an Investigator of the Howard Hughes Medical Institute. In 2014 he was elected a Member of the National Academy of Sciences and has been a Member of the National Academy of Medicine since 2010. He is also member of the Association of American Physicians and a Fellow of the American Association for the Advancement of Science.

      He has received numerous awards, including the Derek Denny-Brown Young Neurological Scholar Award, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, the NIH Director’s Transformative Research Award in 2012, and the NINDS Research Program Award in 2016.

      Dr. Darnell’s academic work began with studies of patients with rare disorders triggered by naturally occurring anti-tumor immune responses that he discovered are caused by antigen-specific killer T cells, laying the groundwork for the field of immuno-oncology. His analysis of the target antigens led him to discover brain-specific systems governing the regulation of RNA, the transcribed copies of our genes. He developed CLIP, a new platform technology that is being widely applied in neurobiology, cancer and inflammatory disease. His work at the New York Genome Center is focused on harnessing the revolution created by the recent dramatic cost reduction in genomic sequencing as well as rapidly advancing information and other technology, utilizing those advances to transform healthcare. He works with the 12 Institutional Founding Members and a growing list of Associate Members from academia and industry including IBM to help develop tools capable of analyzing the massive amounts of data genomic sequencing produces into clinically actionable outcomes.
 He is Principle Investigator on NYGCs NIH Center for Common Disease Genomics Grant from the National Human Genome Research Institute, the Accelerating Medicines Partnership grant from the National Institute of Arthritis and Musculoskeletal Diseases, and the Sohn Foundation Grant for Pediatric Cancer Research.

      Dr. Darnell has studied and worked at a number of the New York Genome Center’s Institutional Founding Members, including Columbia University, The Mount Sinai School of Medicine, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, The Jackson Laboratory and The Rockefeller University. He has been involved with the growth and advancement of the New York Genome Center since its inception in 2010, as a member of the original group of New York scientists that helped to shape NYGC’s early direction.


    • +
      Cheryl A. Moore

      CherylMoore220x200Cheryl A. Moore serves as President and Chief Operating Officer at the New York Genome Center. Ms. Moore is responsible for the financial and operational functions of the Genome Center, partnering with Robert B. Darnell, Chief Executive Officer and Founding Director, to set strategic direction and make key decisions for the organization.

      Ms. Moore has a long history and extensive experience in leading research organizations. Before joining NYGC, she served for six years as the Executive Vice President and Chief Operating Officer of the Howard Hughes Medical Institute (HHMI), a $19B medical research organization, where she led collaborative strategic efforts and supervised key operational functions. From 2004 until 2010, Ms. Moore served as the founding Chief Operating Officer of HHMI’s Janelia Research Campus, an innovative hub in Northern Virginia, where she played a pivotal role in Janelia’s startup. At Janelia, Ms. Moore guided development and implementation of its operating strategy, overseeing all operational aspects of the campus and its $100+ million annual budget.

      Prior to joining HHMI, Ms. Moore served as Senior Vice President and Chief Operating Officer of the Sanford-Burnham Medical Research Institute in La Jolla, CA and previously held top management positions in both start-up and public healthcare companies that experienced intense periods of growth. Prior to her work in biomedical research, she served as a C-Suite leader at a healthcare company which grew from $5M to $1B over five years through acquisitions, and then helped the company prepare for its Initial Public Offering (IPO).

      With her diverse experience as both a founder and change leader in the for-profit and nonprofit arenas, Ms. Moore is known for her strategic ability to resolve performance bottlenecks, develop innovation intense environments, implement systems, and rationalize operations. Throughout her career, she has applied these skills across organizations at differing levels of maturity in the fields of healthcare, technology, biomedical research, and financial services, bringing more than 20 years of strategic executive experience in collaborative leadership involving some of the world’s highest-performing scientists and physicians.

      Ms. Moore has long played a leadership role in community and industry activities. She currently serves as Chair of the Wellcome Trust Centres Review Committee, and has served as Co-Chair of the Board of the Economic Club of Washington, DC. Ms. Moore served on the Virginia Governor’s Bioscience Strategic Initiatives Task Force, and was appointed by the Governor to the Virginia Biotechnology Research Park Authority Board. She also served on the Advisory Boards of the Human Vaccines Project, the Krasnow Institute for Advanced Study at George Mason University, the Virginia campus of George Washington University, and the Virginia Biotechnology Association. Previously, she served on the Board of the Association of Independent Research Institutes, and was appointed by the Virginia Secretary of Technology to serve on the Grant Allocation Committee of the Commonwealth Technology Research Fund.

      Ms. Moore has been honored as one of the top 25 “Women Who Mean Business” by the Washington Business Journal and has also been nominated for the Athena Pinnacle Award, honoring women who forge paths of leadership.

      Outside of her professional roles, Ms. Moore enjoys strength training, running, hiking, walking, being outdoors, eating great food, enjoying theater and the arts, travel, boating, and spending time with friends and family. She’s excited to join the New York Genome Center community and looks forward to exploring all that New York has to offer.

    • +
      Tom Maniatis, PhD


      Scientific & Clinical Steering Committee Chair | Columbia University

      Tom Maniatis is a cofounder of the New York Genome Center, and one of the pioneers of modern molecular biology, having led the development of recombinant DNA methods and their application to the study of the mechanisms of gene regulation. He coauthored the definitive laboratory manual on genetic engineering, the Molecular Cloning Manual, along with Joe Sambrook and Ed Fritsch in 1982. This three-volume manual published by the Cold Spring Harbor Laboratory set a standard for international dissemination of recombinant DNA methods. Dr. Maniatis’ research has led to major advances in understanding the mechanisms of gene expression at the level of RNA transcription and splicing. His current research is focused on the role of single cell diversity in neural connectivity, and on the molecular mechanisms that underlie the neurodegenerative disease ALS (Lou Gehrig’s disease).

      Dr. Maniatis’ research contributions have been acknowledged by membership in the U.S. National Academy of Sciences and the Institute of Medicine, and by numerous awards, including, the Eli Lilly Research Award in Microbiology and Immunology, the Novartis Drew Award in Biomedical Research, the Richard Lounsbery Award for Biology and Medicine, and the Lasker Koshland Special Achievement Award in Medical Science. After receiving his BA and MS from the University of Colorado at Boulder and his PhD in molecular biology from Vanderbilt University, Dr. Maniatis carried out postdoctoral studies at Harvard and the Medical Research Council Laboratory of Molecular Biology in Cambridge, England. He has held faculty appointments at Harvard University, the Cold Spring Harbor Laboratory, and the California Institute of Technology.

    • +
      David Goldstein, PhD

      Goldstein-photo-2-July-2011_thumb2David Goldstein, PhD, is the John E. Borne Professor of Genetics and Development at Columbia University Medical Center (CUMC), and serves as Director of the Institute for Genomic Medicine, in partnership with NewYork-Presbyterian Hospital. He is an Associate faculty member at NYGC, serving in a senior advisory role for the CGND. Dr. Goldstein also plays a leadership advisory role on planning scientific initiatives at NYGC.

      At CUMC and NewYork-Presbyterian Hospital, Dr. Goldstein is building a program that comprehensively integrates genetics and genomics into research, patient care, and education.  He is also developing programs to prepare students for careers in the expanding field of genomic and personalized medicine.  Dr. Goldstein’s role includes serving as an adviser to Columbia University President Lee C. Bollinger and Executive Vice President for Health and Biomedical Sciences Lee Goldman, MD, on the genetic and genomic components of Columbia’s university-wide initiative in precision or personalized medicine.

      Dr. Goldstein was trained in theoretical population genetics, earning his PhD in biological sciences from Stanford in 1994. His research has focused on identifying the relationship between human genetic variations and diseases such as epilepsy, hepatitis C, and schizophrenia, as well as the response of these diseases to pharmacologic treatments.

      Previously, Dr. Goldstein was Director of the Center for Human Genome Variation and the Richard and Pat Johnson Distinguished University Professor at Duke University, with appointments in the departments of molecular genetics & microbiology and biology. Prior to joining Duke, Dr. Goldstein was Professor of Genetics at University College London.

      A recognized expert in his field, Dr. Goldstein has authored over 200 scholarly publications in the areas of population and medical genetics. He received the Royal Society/Wolfson research merit awards in the UK for work in human population genetics, the Triangle Business Journal Health Care Heroes Award: Innovator/Researcher Award (2008), and the University of North Carolina Clinical Services Award (2012). In 2013, Dr. Goldstein chaired the Gordon Research Conference in Human Genetics & Genomics, and was elected a fellow of the American Association for the Advancement of Science. Dr. Goldstein currently serves on the Advisory Council at NIH’s National Institute of Neurological Disorders and Stroke.

    • +
      Dr. Richard Mayeux

      mayeux-formal-picture_websizeDr. Richard Mayeux is the Gertrude H. Sergievsky Professor of Neurology, Psychiatry and Epidemiology, chair of the Department of Neurology at Columbia University College of Physicians and Surgeons, and Neurologist-in-Chief at NewYork-Presbyterian/Columbia University Medical Center. Dr. Mayeux is also director of the Gertrude H. Sergievsky Center, a center devoted to the epidemiologic investigation of neurological diseases, and co-director of the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain at Columbia University Medical Center. 

      Dr. Mayeux has led a multidisciplinary, population-based investigation of Alzheimer’s disease and related disorders known as the Washington Heights-Inwood Community Aging Project (WHICAP) since 1989. Utilizing this WHICAP population, he and his colleagues were among the first to integrate genetic risk factors and epidemiological principles in an attempt to identify biological markers of susceptibility to degenerative diseases of the aging nervous system. He studies the rates and risk factors for Alzheimer’s disease among elderly of mainly African-American and Caribbean Hispanic descent. Dr. Mayeux also directs a genetic study of Alzheimer’s disease in Caribbean Hispanic families. He has completed two full genome-wide scans in these families and is working to fine map regions of interest. He recently identified genetic variants in the sortilin-related receptor, SORL1, related to Alzheimer’s disease.

      Dr. Mayeux is the coordinating investigator for the National Institute on Aging Late Onset Alzheimer’s Disease Family Study. This study began in 2002 with the goal of identifying 1,000 families multiply affected by Alzheimer’s disease. Most recently, he is the lead investigator in a collaborative study of families that display exceptional survival and longevity.

      He has been the author of over 350 papers, chapters, and books dealing with various aspects of Alzheimer’s disease and other degenerative diseases of the aging brain. Dr. Mayeux has been the Robert Aird Visiting Professor at the University of California at San Francisco, the Emanuel Goldberg Visiting Professor at the University of Rochester, and the J.L. Silversides Visiting Professor at the University of Toronto. He was the recipient of the Columbia University Dean’s Distinguished Clinical Scientist Award, and received the Rita Hayworth Award from the Alzheimer’s Association.

      Dr. Mayeux is a fellow of the American Academy of Neurology and the New York Academy of Science, a member of the American Neurological Association and the Association of American Physicians. He is also a member of the Association for Research in Nervous and Mental Disease, the Society for Epidemiologic Research, and the Society for Neuroscience. He has served as a member of the Aging Review and the Epidemiology of Chronic Disorders Committees for the National Institutes of Health and the Medical and Scientific Advisory Board for the Alzheimer’s Association. In 2001, he was elected to the Institute of Medicine of the National Academies. He has received the 2007 Potamkin Prize from the American Academy of Neurology, the 2008 John Stearns Award for Lifetime Achievement in Medicine from the New York Academy of Medicine, and the 2009 Henry Wisniewski Lifetime Achievement Award in Alzheimer’s Disease Research from the Alzheimer’s Association.

  • +
    • +
      Jan Bergmann

      8dd56f_24a295eceef04f6bbc7f3edb059ac265Jan studied biology at the University of Heidelberg in Germany and obtained a M.Sc. by research in life sciences from the University of Edinburgh in Scotland. He joined the laboratory of Prof. William Earnshaw, also at Edinburgh University, where he received his Ph.D. in Cell- and Molecular Biology for his seminal work demonstrating the relationship between local chromatin state, non-coding transcription and the epigenetic inheritance of the centromere locus in mammalian cells. In 2010, Dr. Bergmann moved to New York as postdoctoral fellow in Prof. David Spector’s group at Cold Spring Harbor Laboratory. Here, he spear-headed next-generation sequencing and computational approaches to identify a series of long non-coding RNAs as developmental biomarkers and potential targets for antisense oligonucleotide therapeutics.

    • +
      Ariel Shepley-McTaggart

      8dd56f_ece4c4a131124cf298ed803bed04b57eAriel Shepley-McTaggart graduated Columbia University with a BA in May 2014. Ariel splits her time between her life as a professional ballerina and personal trainer to volunteer in our lab several days a week. She works closely with Catherine Braine, investigating the role of TGF-B in a mouse model of ALS. Ariel will attend University of Pennsylvania School of Veterinary Medicine in Fall 2016.

This work was partially supported by a gift from the Simons Foundation.